The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease

Behavioural Brain Research

Volumn 203, Issue 2, 2009, Pages 304-307

  Kelsey, J E ^a   Harris, O ^a   Cassin, J ^a  

^a BATES COLLEGE   (United States)

Author keywords

6 OHDA; CB1 receptors; Forepaw stepping; l DOPA; Parkinson's; Rimonabant

Indexed keywords

LEVODOPA; RIMONABANT;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; MALE; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HYPOKINESIA; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PIPERIDINES; PYRAZOLES; RATS; RATS, LONG-EVANS; RECEPTOR, CANNABINOID, CB1;

EID: 67649644733     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.04.035     Document Type: Article

References (16)

1. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14 (2001) 1827-1832
2. Mailleux P., and Vanderhaeghen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61 (1993) 1705-1712
3. 1 receptor mRNA levels in the caudate-putamen. Life Sci 66 (2000) 485-494
4. 1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18 (2005) 591-601
5. 1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073-1074 (2006) 209-219
6. van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 19 (2005) 1140-1142
7. Chang J.W., Wachtel S.R., Young D., and Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88 (1999) 617-628
8. Kelsey J.E., Mague S.D., Pijanowski R.S., Harris R.C., Kleckner N.W., and Matthews R.T. NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology (Berl) 175 (2004) 179-188
9. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152 (1998) 259-277
10. Winkler C., Sauer H., Lee C.S., and Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16 (1996) 7206-7215
11. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (2006), Academic Press, Inc., San Diego, CA
12. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15 (1995) 3863-3875
13. 1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat. Psychopharmacology (Berl) 201 (2009) 529-539
14. 1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37 (2000) 71-80
15. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., and Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137 (2006) 337-361
16. 1 agonist, and caffeine on l-DOPA-induced dyskinesia in a 6-OHDA rat model of Parkinson's disease.892.10 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience; 2007 (online).